Ok_老虎社区_美港股上老虎

BBBBBBBBBB
2021-12-23

Labcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition

Laboratory Corp of America Holdings has agreed to acquire Personal Genome Diagnostics Inc (PGDx), a

Labcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":698938866,"tweetId":"698938866","gmtCreate":1640272998270,"gmtModify":1640273006401,"author":{"id":3581562365927542,"authorId":3581562365927542,"authorIdStr":"3581562365927542","name":"BBBBBBBBBB","avatar":"https://static.tigerbbs.com/973395458d7e1db24dbd4a689c79e8a2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698938866","repostId":1133161256,"repostType":4,"repost":{"id":"1133161256","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640269130,"share":"https://www.laohu8.com/m/news/1133161256?lang=&edition=full","pubTime":"2021-12-23 22:18","market":"us","language":"en","title":"Labcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=1133161256","media":"Benzinga","summary":"Laboratory Corp of America Holdings has agreed to acquire Personal Genome Diagnostics Inc (PGDx), a ","content":"<p><b>Laboratory Corp of America Holdings</b>&nbsp;has agreed to acquire&nbsp;Personal Genome Diagnostics Inc (PGDx), a cancer genomics firm with a portfolio of comprehensive liquid biopsy and tissue-based products.</p>\n<ul>\n <li>Labcorp will pay $450 million in cash at closing and up to an additional $125 million on achieving future performance milestones.</li>\n <li>The addition of PGDx complements &amp; accelerates Labcorp’s existing liquid biopsy capabilities and expands its oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities.</li>\n <li>PGDx offers the only diagnostic kit cleared by the FDA for pan-solid cancer comprehensive tumor profiling using a 500+ gene panel.</li>\n <li>PGDx 2021 revenues are expected to be approximately $22 million, with projected revenues for 2022 expected to be nearly $40 million.</li>\n <li>Labcorp expects the acquisition to be slightly dilutive to its adjusted EPS over the next couple of years and provide returns over its cost of capital by year five.</li>\n <li>The transaction is expected to close in 1H of 2022.</li>\n <li><b>Price Action</b>: LH shares closed higher by 0.54% at $304.22 on Wednesday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Labcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLabcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-23 22:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Laboratory Corp of America Holdings</b>&nbsp;has agreed to acquire&nbsp;Personal Genome Diagnostics Inc (PGDx), a cancer genomics firm with a portfolio of comprehensive liquid biopsy and tissue-based products.</p>\n<ul>\n <li>Labcorp will pay $450 million in cash at closing and up to an additional $125 million on achieving future performance milestones.</li>\n <li>The addition of PGDx complements &amp; accelerates Labcorp’s existing liquid biopsy capabilities and expands its oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities.</li>\n <li>PGDx offers the only diagnostic kit cleared by the FDA for pan-solid cancer comprehensive tumor profiling using a 500+ gene panel.</li>\n <li>PGDx 2021 revenues are expected to be approximately $22 million, with projected revenues for 2022 expected to be nearly $40 million.</li>\n <li>Labcorp expects the acquisition to be slightly dilutive to its adjusted EPS over the next couple of years and provide returns over its cost of capital by year five.</li>\n <li>The transaction is expected to close in 1H of 2022.</li>\n <li><b>Price Action</b>: LH shares closed higher by 0.54% at $304.22 on Wednesday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LH":"徕博科"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133161256","content_text":"Laboratory Corp of America Holdings has agreed to acquire Personal Genome Diagnostics Inc (PGDx), a cancer genomics firm with a portfolio of comprehensive liquid biopsy and tissue-based products.\n\nLabcorp will pay $450 million in cash at closing and up to an additional $125 million on achieving future performance milestones.\nThe addition of PGDx complements & accelerates Labcorp’s existing liquid biopsy capabilities and expands its oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities.\nPGDx offers the only diagnostic kit cleared by the FDA for pan-solid cancer comprehensive tumor profiling using a 500+ gene panel.\nPGDx 2021 revenues are expected to be approximately $22 million, with projected revenues for 2022 expected to be nearly $40 million.\nLabcorp expects the acquisition to be slightly dilutive to its adjusted EPS over the next couple of years and provide returns over its cost of capital by year five.\nThe transaction is expected to close in 1H of 2022.\nPrice Action: LH shares closed higher by 0.54% at $304.22 on Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":994,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}